Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

SABCS 2010 /
FIRST trial follow up results

8th - 12th Dec 2010

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 01.02.11
Views: 6744
Rating:

Prof John Robertson - University of Nottingham, UK

Prof Robertson talks to ecancertv at the 2010 San Antonio Breast Cancer Symposium about fulvestrant (500mg dose) in comparison to the aromatase inhibitor, anastrozole, when used as a first-line treatment for hormone receptor positive breast cancer. Follow-up data from the FIRST (FASLODEX fIRst line Study comparing endocrine Treatments) trial - a randomised, open-label, phase II trial in postmenopausal women with locally advanced or metastatic disease - showed a 34% reduction in risk of progression with fulvestrant 500mg compared with anastrozole. Prof Robertson considers impact in the clinic and potential future research.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation